Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Jul 5;78(7):1569-1585.
doi: 10.1093/jac/dkad139.

Invasive candidiasis: current clinical challenges and unmet needs in adult populations

Affiliations
Review

Invasive candidiasis: current clinical challenges and unmet needs in adult populations

Alex Soriano et al. J Antimicrob Chemother. .

Abstract

Invasive candidiasis (IC) is a serious infection caused by several Candida species, and the most common fungal disease in hospitals in high-income countries. Despite overall improvements in health systems and ICU care in the last few decades, as well as the development of different antifungals and microbiological techniques, mortality rates in IC have not substantially improved. The aim of this review is to summarize the main issues underlying the management of adults affected by IC, focusing on specific forms of the infection: IC developed by ICU patients, IC observed in haematological patients, breakthrough candidaemia, sanctuary site candidiasis, intra-abdominal infections and other challenging infections. Several key challenges need to be tackled to improve the clinical management and outcomes of IC patients. These include the lack of global epidemiological data for IC, the limitations of the diagnostic tests and risk scoring tools currently available, the absence of standardized effectiveness outcomes and long-term data for IC, the timing for the initiation of antifungal therapy and the limited recommendations on the optimal step-down therapy from echinocandins to azoles or the total duration of therapy. The availability of new compounds may overcome some of the challenges identified and increase the existing options for management of chronic Candida infections and ambulant patient treatments. However, early identification of patients that require antifungal therapy and treatment of sanctuary site infections remain a challenge and will require further innovations.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Current clinical challenges of IC.
Figure 2.
Figure 2.
All-cause mortality rates in IC randomized trials (based on data reported by Demir). The figure does not account for differences in study design, namely number of patients randomized, and only includes antifungals currently reimbursed. AMB, amphotericin B; 5-Flu, 5-fluorocytosine; LAMB, lipid formulation of amphotericin B.

References

    1. Kullberg BJ, Arendrup MC. Invasive candidiasis. N Engl J Med 2015; 373: 1445–56. 10.1056/NEJMra1315399 - DOI - PubMed
    1. Logan C, Martin-Loeches I, Bicanic T. Invasive candidiasis in critical care: challenges and future directions. Intensive Care Med 2020; 46: 2001–14. 10.1007/s00134-020-06240-x - DOI - PubMed
    1. Bongomin F, Gago S, Oladele ROet al. . Global and multi-national prevalence of fungal diseases-estimate precision. J Fungi (Basel) 2017; 3: 57. 10.3390/jof3040057 - DOI - PMC - PubMed
    1. Clancy CJ, Pappas PG, Vazquez Jet al. . Detecting infections rapidly and easily for candidemia trial, part 2 (DIRECT2): a prospective, multicenter study of the T2Candida panel. Clin Infect Dis 2018; 66: 1678–86. 10.1093/cid/cix1095 - DOI - PubMed
    1. Martinez-Jimenez MC, Munoz P, Guinea Jet al. . Potential role of Candida albicans germ tube antibody in the diagnosis of deep-seated candidemia. Med Mycol 2014; 52: 270–5. 10.1093/mmy/myt025 - DOI - PubMed

Publication types

Supplementary concepts